[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368084-105":59,"doc-detail-368084-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","lack-of-association-between-prior-or-concurrent-malignancies-and-overall-survival-in-gastroesophageal-cancer-evidence-from-a-large-european-single-center-cohort","Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort","","Background History of malignant disease is a common exclusion criterion in clinical cancer trials, yet data on the impact of cancer survivorship on outcome in gastroesophageal cancer patients are scarce. Retrospective association analyses evaluated self-reported prior or concurrent malignancies with patient and tumor characteristics, symptoms, and overall survival among 1491 patients treated at the Medical University of Vienna from 2000 to 2021. Results assessed frequencies and statistical associations.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lack-of-association-between-prior-or-concurrent-malignancies-and-overall-survival-in-gastroesophageal-cancer-evidence-from-a-large-european-single-center-cohort/368084/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lack-of-association-between-prior-or-concurrent-malignancies-and-overall-survival-in-gastroesophageal-cancer-evidence-from-a-large-european-single-center-cohort/368084.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why are prior or concurrent malignancies often excluded from clinical cancer trials?","Question",{"text":112,"@type":113},"The article notes such cases are frequently used as exclusion criteria because they are often believed to be associated with worse outcomes. The study aims to question this assumption in gastroesophageal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many gastroesophageal cancer patients were included, and what did the study assess?",{"text":117,"@type":113},"The analysis included 1491 patients treated between 01/01/2000 and 31/12/2021. It assessed self-reported prior or concurrent malignancies alongside patient characteristics, tumor characteristics, symptoms, and overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"Were prior or concurrent malignancies associated with overall survival in this cohort?",{"text":121,"@type":113},"No statistically significant association was found between history of other primary malignancies (and the number of other cancer entities) and overall survival (OS).",{"name":123,"@type":110,"acceptedAnswer":124},"What factors were associated with a history of other malignancies?",{"text":125,"@type":113},"History of other malignancies was associated with older age, squamous cell histology, less aggressive localized tumor stages, and fewer acid reflux, based on the reported p-values.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368084,1790740706,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Clinical and Translational Oncology (2026) 28:942–952  \n[https://doi.org/10.1007/s12094-025-04036-3](https://doi.org/10.1007/s12094-025-04036-3)  \nLack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single‑center cohort  \nHannah C. Puhr1,2 · Luzia Berchtold1,3 · Linda Zingerle1,2 · Martin Korpan1,2 · Julia M. Berger1,2 · Gerd Jomrich4 · Reza Asari4 · Sebastian F. Schoppmann4 · Gerald W. Prager1,2 · Elisabeth S. Bergen1,2 · Anna S. Berghoff1,2 · Matthias Preusser1,2 · Aysegül Ilhan‑Mutlu1,2  \nReceived: 19 May 2025 / Accepted: 15 August 2025 / Published online: 29 August 2025 © The Author(s) 2025  \nAbstract  \nBackground History of malignant disease is a common exclusion criterion in clinical cancer trials, yet data on the impact of cancer survivorship on outcome in gastroesophageal cancer patients are scarce.  \nMethods Retrospective association analyses of self-reported prior or concurrent malignancies with patient characteristics, tumor characteristics, symptoms and overall survival (OS) were performed in 1491 gastroesophageal cancers patients treated between 01/01/2000 and 31/12/2021 at the Medical University of Vienna.  \nResults Of 1491 patients 255 (18%) had other primary cancer diagnoses, of which 185 (73%) occurred before, 52 (20%) atthe same time as and 18 (7%) both before and at the same time as gastroesophageal cancer diagnosis. 205 (80%) patients had one, 43 (17%) had 2 and 7 (3%) had 3 other malignancies. History of other malignancies was associated with older age (p \u003C 0.0001), squamous cell histology (p = 0.018), less aggressive localized tumor stages (p = 0.037) and fewer acid reflux (p = 0.011). There was neither an association between history of other primary malignancies nor the number of other cancer entities and OS (p = 0.47; p = 0.43) .  \nConclusion Self-reported history of other malignant diseases is frequent in a real-life European gastroesophageal cancer cohort and was not statistically significantly associated with outcome, but rather with older age and squamous cell histology. Our data emphasize that cancer survivors should not be categorically excluded from clinical cancer trials due to fear of dismal prognosis. Prospective research is warranted to improve eligibility for this subgroup.  \nKeywords Gastric cancer · Esophageal cancer · Other malignancies · Survivorship  \nAbbreviations  \nOS Overall survival  \nHR Hazard ratio  \nCI Confidential interval  \nHER2 Human epidermal growth factor receptor 2 PD-L1 Programmed cell death ligand 1  \nBMI Body mass index  \ndMMR Mismatch repair deficiency CPS Combined positive score TPS Tumor proportion score IQR Interquartile range  \nAC Adenocarcinoma  \nSCC Squamous cell carcinoma  \nFDA U.S. food and drug administration  \nExtended author information available on the last page of the article  \nASCO American society of clinical oncology  \nSEER Surveillance, epidemiology, and end results  \nBackground  \nAs therapeutic strategies evolve, outcome and survival of cancer patients improves, while risk factors for the development of malignancies cumulate with advanced age. These include non-modifiable factors such as inherited cancer syndromes like Lynch syndrome and or CDH1 mutations, and modifiable exposures such as obesity, diet, Helicobacter pylori infection, chronic gastroesophageal reflux, smoking, and heavy alcohol use [1]. Many of these factors play a role not only in the development of the first malignancy but also in increasing the risk of subsequent cancers later in life.  \nThus, patients often suffer from multiple malignant diseases throughout their life and cancer survivors are known to be at higher risk for cancer development than the general population [2–4] . However, prior or concurrent malignant diseases—either altogether or within 24 months before trial initiation—are frequent exclusion criteria in clinical trials, as these patients are often believed to have worse outcome [5","cbCaie8G2GmeA6uS","https://ap.wps.com/l/cbCaie8G2GmeA6uS","pdf",769725,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n# Methods\n## Patient and data recruitment","[{\"question\":\"Why are prior or concurrent malignancies often excluded from clinical cancer trials?\",\"answer\":\"The article notes such cases are frequently used as exclusion criteria because they are often believed to be associated with worse outcomes. The study aims to question this assumption in gastroesophageal cancer.\"},{\"question\":\"How many gastroesophageal cancer patients were included, and what did the study assess?\",\"answer\":\"The analysis included 1491 patients treated between 01/01/2000 and 31/12/2021. It assessed self-reported prior or concurrent malignancies alongside patient characteristics, tumor characteristics, symptoms, and overall survival.\"},{\"question\":\"Were prior or concurrent malignancies associated with overall survival in this cohort?\",\"answer\":\"No statistically significant association was found between history of other primary malignancies (and the number of other cancer entities) and overall survival (OS).\"},{\"question\":\"What factors were associated with a history of other malignancies?\",\"answer\":\"History of other malignancies was associated with older age, squamous cell histology, less aggressive localized tumor stages, and fewer acid reflux, based on the reported p-values.\"}]","Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort | PDF",1790174907,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8adb3ac9ac40650ceb5ec8ac8151f0ea.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de419f6695168471f328afb4afa905e9.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07b2fe77364bcd66917859013b688af5.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a1e3a6ae55abcee69f0fb65f8b95200.webp",980,1301]